Taken together, ablation of CCR2-MCP1 signaling boosts anti-tumor efficacy by preventing the tumor infiltration of immunosuppressive CCR2+ M2 MDSCs and by promoting cytotoxic T cell responses, and may serve as a new therapeutic component in immuno-oncology. This evidence concerns the gene CCR2 and neoplasm.